OverviewSuggest Edit

Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

TypePublic
Founded1996
HQTampa, US
Websiteoragenics.com

Latest Updates

Employees (est.) (Dec 2018)6
Revenue (FY, 2016)$0(-100%)
Share Price (Jun 2019)$0.5 (-1%)

Key People/Management at Oragenics

Alan Joslyn

Alan Joslyn

President and Chief Executive Officer
Michael Sullivan

Michael Sullivan

CFO
Martin Handfield

Martin Handfield

Senior Vice President of Discovery Research
Show more

Oragenics Office Locations

Oragenics has an office in Tampa
Tampa, US (HQ)
4902 Eisenhower Blvd N #125
Show all (1)

Oragenics Financials and Metrics

Oragenics Revenue

USD

Net income (Q2, 2019)

(4.8m)

EBIT (Q2, 2019)

(4.9m)

Market capitalization (10-Jun-2019)

21.8m

Closing stock price (10-Jun-2019)

0.5

Cash (30-Jun-2019)

25.7m
Oragenics's current market capitalization is $21.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.0m939.9k1.2m

Revenue growth, %

(9%)25%(100%)

Cost of goods sold

343.4k369.6k481.7k

Gross profit

688.9k570.3k694.1k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

214.7k303.8k201.0k242.0k329.8k262.3k

Cost of goods sold

79.8k125.6k73.7k86.8k134.6k90.0k

Gross profit

134.9k178.1k127.3k155.3k195.2k172.3k

Gross profit Margin, %

63%59%63%64%59%66%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

16.3m10.4m5.1m4.1m6.2m20.2m

Accounts Receivable

64.4k21.1k24.1m

Inventories

288.4k119.4k321.5k141.1k

Current Assets

16.8m11.0m5.6m4.2m7.2m21.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

14.6m12.9m11.8m9.1m8.0m6.7m3.4m5.5m5.1m2.2m2.1m2.9m4.8m3.9m13.8m29.3m25.7m

Accounts Receivable

42.9k22.8k26.3k26.8k19.4k32.7k

Inventories

265.9k239.0k263.9k377.0k364.1k299.3k241.5k

Current Assets

15.1m13.3m12.3m9.6m8.5m7.2m3.8m6.0m5.3m2.3m4.5m5.1m5.5m5.2m15.5m31.1m26.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(16.1m)(5.8m)(11.7m)(7.0m)(6.7m)(9.9m)

Depreciation and Amortization

76.5k27.7k71.2k75.0k65.8k30.1k

Inventories

203.6k214.8k66.1k229.3k

Accounts Payable

(234.5k)(199.7k)331.1k446.0k525.8k225.3k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.6m)(3.5m)(4.6m)(7.6m)(9.5m)(2.1m)(2.4m)(4.3m)(2.0m)(3.2m)(5.3m)(2.1m)(4.4m)(7.2m)(3.3m)(8.1m)

Depreciation and Amortization

6.5k13.3k20.1k32.5k52.5k18.3k36.5k55.4k18.0k35.7k53.3k7.7k11.0k18.4k12.9k26.2k

Accounts Payable

(102.6k)(206.7k)(305.6k)(161.5k)51.6k17.0k(137.5k)(44.8k)(174.6k)(216.1k)317.2k293.4k719.1k548.5k931.8k697.7k

Cash From Operating Activities

(1.6m)(3.3m)(4.4m)(2.2m)(3.5m)(1.7m)(3.5m)(5.1m)(1.9m)(3.7m)(5.0m)(1.4m)(3.6m)(6.1m)(2.2m)(5.7m)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Oragenics Online and Social Media Presence

Embed Graph

Oragenics News and Updates

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Oragenics, Inc. (NYSE American: OGEN). If you...

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oragenics Blogs

Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced that Alan Joslyn, president and CEO of Oragenics, Inc. will be a featured presenter…

Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in …

Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting at the American Peptide Symposium on their novel peptide syn…

Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a collaborative study investigating an …

Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious disea…

Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lanti…
Show more

Oragenics Frequently Asked Questions

  • When was Oragenics founded?

    Oragenics was founded in 1996.

  • Who are Oragenics key executives?

    Oragenics's key executives are Alan Joslyn, Michael Sullivan and Martin Handfield.

  • How many employees does Oragenics have?

    Oragenics has 6 employees.

  • Who are Oragenics competitors?

    Competitors of Oragenics include Elexxion, Livionex Pharma and Heartland Dental.

  • Where is Oragenics headquarters?

    Oragenics headquarters is located at 4902 Eisenhower Blvd N #125, Tampa.

  • Where are Oragenics offices?

    Oragenics has an office in Tampa.

  • How many offices does Oragenics have?

    Oragenics has 1 office.